NCT01398046View on ClinicalTrials.gov

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Healthy
Interventions
DRUG

Dasatinib

dasatinib (100mg) PO x1

DRUG

Dasatinib plus Rabeprazole

Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)

DRUG

Dasatinib plus Rabeprazole AND Betaine Hydrochloride

Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4

Trial Locations (1)

94143

Clinical Research Center, UCSF, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT01398046 - Effects of Gastric pH on the Pharmacokinetics of Dasatinib | Biotech Hunter | Biotech Hunter